AnaptysBio Announces Agreement with Roche to Develop Novel Antibodies
News Jan 12, 2010
AnaptysBio, Inc., announced that it has signed an agreement with Roche for the development of novel antibody therapeutics.
“We look forward to assisting Roche in building its pipeline of product possibilities as we also apply the platform to generate our own novel product candidates.”
Under the terms of the agreement, AnaptysBio will be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) platform. Roche will receive a worldwide license to develop and commercialize antibodies optimized by AnaptysBio. In addition to a signing fee paid by Roche, AnaptysBio will be eligible to receive milestone payments and royalties upon product sales.
“AnaptysBio’s proprietary SHM platform provides a powerful new approach for evolving existing antibodies to meet challenging therapeutic design goals such as those specified by Roche,” said Tom Smart, chairman and chief executive officer for AnaptysBio. “We look forward to assisting Roche in building its pipeline of product possibilities as we also apply the platform to generate our own novel product candidates.”
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE
Protein That Helps Keep Breast Cancer Dormant IdentifiedNews
A protein kinase that stops breast cancer cells growing and spreading has been outlined in new research.READ MORE
Barrier to Liquid Biopsies Overcome with Blood Stabilization TechniqueNews